Ligand Pharmaceuticals Incorporated (LGND)

$72.52

-6.35

(-8.05%)▲

Market is closed - opens 7 PM, 19 Apr 2024

Insights on Ligand Pharmaceuticals Incorporated

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 32.86M → 28.10M (in $), with an average decrease of 14.5% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -12.79M → 18.18M (in $), with an average increase of 170.3% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 46.7% return, outperforming this stock by 43.2%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 245.1% return, outperforming this stock by 292.6%

Performance

  • $72.50
    $78.70
    $72.52
    downward going graph

    0.03%

    Downside

    Day's Volatility :7.88%

    Upside

    7.85%

    downward going graph
  • $49.24
    $94.57
    $72.52
    downward going graph

    32.1%

    Downside

    52 Weeks Volatility :47.93%

    Upside

    23.32%

    downward going graph

Returns

PeriodLigand Pharmaceuticals IncorporatedSector (Health Care)Index (Russel 2000)
3 Months
10.73%
-0.7%
0.0%
6 Months
46.27%
6.6%
0.0%
1 Year
3.49%
3.7%
-1.5%
3 Years
-45.98%
14.0%
-21.8%

Highlights

Market Capitalization
1.4B
Book Value
$39.92
Earnings Per Share (EPS)
3.03
PE Ratio
26.38
PEG Ratio
1.53
Wall Street Target Price
116.8
Profit Margin
39.72%
Operating Margin TTM
-11.95%
Return On Assets TTM
0.79%
Return On Equity TTM
8.29%
Revenue TTM
131.3M
Revenue Per Share TTM
7.59
Quarterly Revenue Growth YOY
-44.2%
Gross Profit TTM
107.3M
EBITDA
45.5M
Diluted Eps TTM
3.03
Quarterly Earnings Growth YOY
-0.97
EPS Estimate Current Year
4.45
EPS Estimate Next Year
5.6
EPS Estimate Current Quarter
0.66
EPS Estimate Next Quarter
0.97

Analyst Recommendation

Buy
    91%Buy
    8%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Ligand Pharmaceuticals Incorporated(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
11
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 61.06%

Current $72.52
Target $116.80

Company Financials

FY18Y/Y Change
Revenue
251.5M
↑ 78.21%
Net Income
143.3M
↑ 1041.45%
Net Profit Margin
57.0%
↑ 48.1%
FY19Y/Y Change
Revenue
120.3M
↓ 52.17%
Net Income
629.3M
↑ 339.09%
Net Profit Margin
523.19%
↑ 466.19%
FY20Y/Y Change
Revenue
186.4M
↑ 54.98%
Net Income
-3.0M
↓ 100.47%
Net Profit Margin
-1.6%
↓ 524.79%
FY21Y/Y Change
Revenue
277.1M
↑ 48.66%
Net Income
57.1M
↓ 2014.17%
Net Profit Margin
20.62%
↑ 22.22%
FY22Y/Y Change
Revenue
196.2M
↓ 29.19%
Net Income
-5.2M
↓ 109.13%
Net Profit Margin
-2.66%
↓ 23.28%
FY23Y/Y Change
Revenue
131.3M
↓ 33.09%
Net Income
52.2M
↓ 1099.31%
Net Profit Margin
39.72%
↑ 42.38%
Q3 FY22Q/Q Change
Revenue
66.1M
↑ 15.1%
Net Income
404.0K
↓ 145.14%
Net Profit Margin
0.61%
↑ 2.17%
Q4 FY22Q/Q Change
Revenue
50.4M
↓ 23.77%
Net Income
-14.5M
↓ 3697.52%
Net Profit Margin
-28.85%
↓ 29.46%
Q1 FY23Q/Q Change
Revenue
44.0M
↓ 12.71%
Net Income
41.9M
↓ 388.63%
Net Profit Margin
95.38%
↑ 124.23%
Q2 FY23Q/Q Change
Revenue
26.4M
↓ 40.05%
Net Income
2.3M
↓ 94.54%
Net Profit Margin
8.69%
↓ 86.69%
Q3 FY23Q/Q Change
Revenue
32.9M
↑ 24.66%
Net Income
-12.8M
↓ 658.6%
Net Profit Margin
-38.92%
↓ 47.61%
Q4 FY23Q/Q Change
Revenue
28.1M
↓ 14.5%
Net Income
18.2M
↓ 242.18%
Net Profit Margin
64.72%
↑ 103.64%
FY18Y/Y Change
Total Assets
1.3B
↑ 87.89%
Total Liabilities
699.9M
↑ 177.32%
FY19Y/Y Change
Total Assets
1.5B
↑ 16.54%
Total Liabilities
702.1M
↑ 0.31%
FY20Y/Y Change
Total Assets
1.4B
↓ 7.28%
Total Liabilities
652.8M
↓ 7.02%
FY21Y/Y Change
Total Assets
1.3B
↓ 4.47%
Total Liabilities
479.8M
↓ 26.5%
FY22Y/Y Change
Total Assets
762.7M
↓ 41.4%
Total Liabilities
165.2M
↓ 65.57%
FY23Y/Y Change
Total Assets
833.1M
↑ 9.23%
Total Liabilities
130.7M
↓ 20.87%
Q3 FY22Q/Q Change
Total Assets
1.1M
↓ 99.9%
Total Liabilities
234.3K
↓ 99.91%
Q4 FY22Q/Q Change
Total Assets
762.7M
↑ 72493.22%
Total Liabilities
165.2M
↑ 70398.53%
Q1 FY23Q/Q Change
Total Assets
811.1M
↑ 6.35%
Total Liabilities
164.8M
↓ 0.26%
Q2 FY23Q/Q Change
Total Assets
758.1M
↓ 6.53%
Total Liabilities
93.2M
↓ 43.42%
Q3 FY23Q/Q Change
Total Assets
769.2M
↑ 1.46%
Total Liabilities
103.8M
↑ 11.37%
Q4 FY23Q/Q Change
Total Assets
833.1M
↑ 8.3%
Total Liabilities
130.7M
↑ 25.91%
FY18Y/Y Change
Operating Cash Flow
194.1M
↑ 107.4%
Investing Cash Flow
-423.3M
↑ 402.83%
Financing Cash Flow
328.6M
↓ 4467.74%
FY19Y/Y Change
Operating Cash Flow
-29.3M
↓ 115.12%
Investing Cash Flow
466.9M
↓ 210.31%
Financing Cash Flow
-485.2M
↓ 247.65%
FY20Y/Y Change
Operating Cash Flow
54.6M
↓ 286.07%
Investing Cash Flow
231.6M
↓ 50.39%
Financing Cash Flow
-310.5M
↓ 35.99%
FY21Y/Y Change
Operating Cash Flow
78.8M
↑ 44.36%
Investing Cash Flow
30.5M
↓ 86.82%
Financing Cash Flow
-137.8M
↓ 55.64%
FY22Y/Y Change
Operating Cash Flow
137.9M
↑ 74.94%
Investing Cash Flow
163.6M
↑ 436.07%
Financing Cash Flow
-276.0M
↑ 100.34%
Q3 FY22Q/Q Change
Operating Cash Flow
20.5M
↑ 72.5%
Investing Cash Flow
19.2M
↓ 49.34%
Financing Cash Flow
-40.8M
↓ 31.31%
Q4 FY22Q/Q Change
Operating Cash Flow
53.5M
↑ 160.98%
Investing Cash Flow
7.6M
↓ 60.6%
Financing Cash Flow
-5.3M
↓ 87.02%
Q1 FY23Q/Q Change
Operating Cash Flow
33.9M
↓ 36.51%
Investing Cash Flow
10.5M
↑ 39.61%
Financing Cash Flow
-775.0K
↓ 85.37%
Q2 FY23Q/Q Change
Operating Cash Flow
-82.0K
↓ 100.24%
Investing Cash Flow
7.6M
↓ 28.37%
Financing Cash Flow
-67.8M
↑ 8642.84%

Technicals Summary

Sell

Neutral

Buy

Ligand Pharmaceuticals Incorporated is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated
9.33%
46.27%
3.49%
-45.98%
-35.41%
Moderna, Inc.
Moderna, Inc.
-0.79%
20.27%
-27.48%
-36.11%
359.53%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-6.12%
9.1%
11.53%
80.35%
170.35%
Novo Nordisk A/s
Novo Nordisk A/s
-6.29%
23.82%
46.7%
242.59%
414.69%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.44%
6.95%
20.9%
79.35%
133.77%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated
26.38
26.38
1.53
4.45
0.08
0.01
NA
39.92
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.71
25.71
1.46
45.13
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.58
46.58
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.42
28.42
0.53
16.73
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated
Buy
$1.4B
-35.41%
26.38
39.72%
Moderna, Inc.
Moderna, Inc.
Buy
$39.8B
359.53%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.1B
170.35%
25.71
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$551.2B
414.69%
46.58
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$101.9B
133.77%
28.42
36.68%

Institutional Holdings

  • BlackRock Inc

    16.73%

  • Vanguard Group Inc

    10.60%

  • HHG PLC

    7.59%

  • Macquarie Group Ltd

    5.58%

  • State Street Corporation

    3.77%

  • Dimensional Fund Advisors, Inc.

    3.74%

Company Information

ligand, a pharmaceutical company, is assembling a large and diverse portfolio of current and near-term commercial revenue generating assets to assist the long-term financial growth of the company. we operate this business on a lean cost structure that allows us to maximize cash flow and ultimately deliver a meaningful return for our shareholders.

Organization
Ligand Pharmaceuticals Incorporated
Employees
58
CEO
Mr. Matthew E. Korenberg
Industry
Health Technology

Discover More

FAQs